An international collaborative study to assign value for Total Factor XIII-B Subunit Antigen to the WHO 1st International Standard for Factor XIII Plasma, (02/206): Communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen.
FXIII-B subunit
Factor XIII
International Unit
WHO International Standard
monoclonal antibody
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
09
10
2021
accepted:
15
11
2021
pubmed:
17
11
2021
medline:
16
3
2022
entrez:
16
11
2021
Statut:
ppublish
Résumé
Factor XIII (FXIII)-B subunit measurements are required for the diagnosis and characterization of the type of FXIII deficiency. Furthermore, therapy for FXIII-A deficiency with recombinant FXIII (rFXIII-A) relies on available FXIII-B. To carry out a collaborative study to calibrate and assign value to the current WHO 1st International Standard (IS) FXIII Plasma for Total FXIII-B subunit, relative to locally collected normal plasma pools. Laboratories were instructed to use a validated method (specific ELISA antibodies provided) for assessment of Total FXIII-B subunit antigen potency. All laboratories used this method with one laboratory using an additional in-house method. Nine data sets were received from seven laboratories (37 assays in total), which provided a total of 35 valid estimates for this new assignment. Total FXIII-B subunit estimates were calculated relative to locally collected normal plasma pools, using an arbitrary value of 1.00 unit of Total FXIII-B subunit per ml, for each pool. Combination of results produced an overall mean of 0.98 units/mL with an inter-laboratory variability (geometric coefficients of variation - GCV%) of 18.3% [95% confidence interval: 0.86-1.11]. Real-time and bench stability studies indicated good stability and preservation of the FXIII-B subunit analyte in the WHO 1st IS FXIII Plasma (02/206). Following agreement by study participants, ISTH/SSC Experts, WHO-ISTH Liaison Group and the SSC Board, the WHO/ECBS established the current WHO 1st IS Factor XIII plasma (NIBSC code 02/206) by additionally assigning it with a Total FXIII-B subunit antigen value of 0.98 IU/ampoule, in October 2019.
Sections du résumé
BACKGROUND
Factor XIII (FXIII)-B subunit measurements are required for the diagnosis and characterization of the type of FXIII deficiency. Furthermore, therapy for FXIII-A deficiency with recombinant FXIII (rFXIII-A) relies on available FXIII-B.
OBJECTIVE
To carry out a collaborative study to calibrate and assign value to the current WHO 1st International Standard (IS) FXIII Plasma for Total FXIII-B subunit, relative to locally collected normal plasma pools.
METHODS
Laboratories were instructed to use a validated method (specific ELISA antibodies provided) for assessment of Total FXIII-B subunit antigen potency. All laboratories used this method with one laboratory using an additional in-house method. Nine data sets were received from seven laboratories (37 assays in total), which provided a total of 35 valid estimates for this new assignment. Total FXIII-B subunit estimates were calculated relative to locally collected normal plasma pools, using an arbitrary value of 1.00 unit of Total FXIII-B subunit per ml, for each pool.
RESULTS
Combination of results produced an overall mean of 0.98 units/mL with an inter-laboratory variability (geometric coefficients of variation - GCV%) of 18.3% [95% confidence interval: 0.86-1.11]. Real-time and bench stability studies indicated good stability and preservation of the FXIII-B subunit analyte in the WHO 1st IS FXIII Plasma (02/206).
CONCLUSION
Following agreement by study participants, ISTH/SSC Experts, WHO-ISTH Liaison Group and the SSC Board, the WHO/ECBS established the current WHO 1st IS Factor XIII plasma (NIBSC code 02/206) by additionally assigning it with a Total FXIII-B subunit antigen value of 0.98 IU/ampoule, in October 2019.
Identifiants
pubmed: 34784091
doi: 10.1111/jth.15596
pii: S1538-7836(22)02811-2
doi:
Substances chimiques
Fibrinogen
9001-32-5
Factor XIII
9013-56-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
525-531Informations de copyright
© 2021 International Society on Thrombosis and Haemostasis.
Références
Raut S, Merton RE, Rigsby P, et al. A collaborative study to establish the first International Standard for factor XIII plasma. J Thromb Haemost. 2007;5:1923-1929.
Raut S, Belgrave D, Merton RE, Barrowcliffe TW. Proposed 1st International Standard for Factor XIII Plasma (02/206). Final report and recommendations. WHO/BS/04.1994 Rev. 1. https://www.who.int/bloodproducts/publications/04-1994Rev.1factorXIIIRev1.pdf
Poon MC, Russell JA, Low S, et al. Hemopoietic origin of factor XIII A subunits in platelets, monocytes, and plasma. Evidence from bone marrow transplantation studies. J Clin Invest. 1989;84:787-792.
Wölpl A, Lattke H, Board PG, et al. Coagulation factor XIII A and B subunits in bone marrow and liver transplantation. Transplantation. 1987;43:151-153.
Nagy JA, Henriksson P, McDonagh J. Biosynthesis of factor XIII B subunit by human hepatoma cell lines. Blood. 1986;68:1272-1279.
Ichinose A, McMullen BA, Fujikawa K, Davie EW. Amino acid sequence of the b subunit of human factor XIII, a protein composed of ten repetitive segments. Biochemistry. 1986;25:4633-4638.
Muszbek L, Yee V, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res. 1999;94:271-304.
Komaromi I, Bagoly Z, Muszbek L. Factor XIII: novel, structural and functional aspects. J Thromb Haemost. 2011;9:9-20.
Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91:931-972.
Schroeder V, Kohler HP. New developments in the area of Factor XIII. J Thromb Haemost. 2013;11:234-244.
Rodeghiero F, Tosetto A, Di Bona E, Castaman G. Clinical pharmacokinetics of a placenta-derived factor XIII concentrate in type I and type II factor XIII deficiency. Am J Hematol. 1991;36:30-34.
Saito M, Asakura H, Yoshida T, et al. A familial factor XIII B subunit B deficiency. Br J Haemoatol. 1990;74:290-294.
Hashiguchi T, Saito M, Morishita E, Matsuda T, Ichinose A. Two genetic defects in a patient with complete deficiency of the B-subunit for coagulation factor XIII. Blood. 1993;82:145-150.
Yorifuji H, Anderson K, Lynch GW, Van de Water L, McDonagh J. B protein of factor XIII: differentiation between free B and complexed B. Blood. 1988;72(5):1645-1650.
Ajzner É, Schlammadinger Á, Kerényi A, et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII; a novel form of acquired factor XIII deficiency. Blood. 2009;113:723-725. doi:10.1182/blood-2008-09-179333
Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood. 2012;119:5111-5117.
Katona E, Pénzes K, Csapó A, et al. Interaction of factor XIII subunits. Blood. 2014;123:1757-1763.
Finney DJ. Statistical methods in biological assay, 3rd edn. Charles Griffin; 1978.
Daas A. Combistats User Manual v6.0. Strasbourg, France, EDQM, Council of. Europe. 2013. https://www.combistats.eu
Kirkwood TBL. Geometric means and measures of dispersion. Biometrics. 1979;35:908-909.
Grubbs F. Procedures for detecting outlying observations in samples. Technometrics. 1969;11:1-21.